thermalife vs voltaren ?, page-5

Transdel Pharmaceuticals developed in 2010 its new
Ketotransdel:

Ketotransdel uses the
Transdel technology to deliver the
active drug, ketoprofen, a nonsteroidal
anti-inflammatory drug
(NSAID), through the skin. The
drug passes directly into the
underlying tissues where it exerts
its well-known anti-inflammatory
and analgesic effects as demonstrated
in a completed Phase 3
clinical trial. Other partnership or
licensing opportunities include
cosmetic or cosmeceutical products
and co-development opportunities
for the transdermal delivery
of new and existing drugs in
any therapeutic area.

It does sound familiar, doesnt it?
What is important here is the fact that Ketoprofen has some uphill battle to fight in terms of safety concerns of the compound:


Ketoprofen oral

There is certainly competition in the NSAIDs market targeting anti-inflammatory and pain issues which shows
the urgency of leading companies to innovate in this area.
Safety concerns do though play a major role and Novartis would be more than motivated to eradicate concerns surrounding Voltaren.
Would they partner with a company which has similar health concern issues as their main product?
They might prefer a product which already has proven an 18 year old safety record on the market.
Hence the likely condition 2 years ago in Germany for PNO management to have the product on the market again before moving into licensing talks.